A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
about
Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysisDCE-MRI assessment of the effect of Epstein-Barr virus-encoded latent membrane protein-1 targeted DNAzyme on tumor vasculature in patients with nasopharyngeal carcinomasA phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma.Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.Malignant pleural mesothelioma: from the bench to the bedside.Cediranib: a VEGF receptor tyrosine kinase inhibitor.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.Distributed capillary adiabatic tissue homogeneity model in parametric multi-channel blind AIF estimation using DCE-MRI.Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.The role of Cediranib in ovarian cancer.Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
P2860
Q33414769-E76F6888-5054-4C60-85FD-EA0F85A32CB4Q33926377-CF2D2DAD-AC19-41D5-8C75-D66A484FA438Q34582022-5E9FB88B-F617-485A-BEED-1035719BAF56Q35225267-2D37C173-D68A-484E-994C-1ABA8096AD09Q37983692-C4642653-DC56-4FD9-AEC3-8F8523A0E7C6Q38019747-FFCC1601-D518-4D0F-AAFE-7EDC3DE96077Q38029363-A35352EE-7CFD-490B-8EB9-E7D60A51B6D8Q39036230-1A6AB366-351F-4F82-AB68-CF7A7755B191Q41085496-CC236DC7-1699-45C5-85C9-9E77F0F74870Q48352556-B9E5C7A0-8F4D-4410-BCE7-B979C6B99B1CQ49966031-A140545E-0EE7-49C4-B9FF-5FF4F0FE2638Q50885562-DE7C9E7A-0AFE-4644-9E72-276633D51F36Q53188383-F909B562-0B60-4761-B8D2-E6B4FB8457EC
P2860
A two-part phase II study of cediranib in patients with advanced solid tumours: the effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
A two-part phase II study of c ...... and imaging pharmacodynamics.
@en
A two-part phase II study of c ...... and imaging pharmacodynamics.
@nl
type
label
A two-part phase II study of c ...... and imaging pharmacodynamics.
@en
A two-part phase II study of c ...... and imaging pharmacodynamics.
@nl
prefLabel
A two-part phase II study of c ...... and imaging pharmacodynamics.
@en
A two-part phase II study of c ...... and imaging pharmacodynamics.
@nl
P2093
P2860
P50
P1476
A two-part phase II study of c ...... y and imaging pharmacodynamics
@en
P2093
A Fielding
Claire L Mitchell
J P B O'Connor
M Middleton
P2860
P2888
P304
P356
10.1007/S00280-010-1534-3
P577
2010-12-01T00:00:00Z